Key points
- The federal workplace urine panel looks for marijuana, cocaine, opioids, PCP, fentanyl and amphetamines. It doesn't list psilocybin, psilocin, muscimol, kratom or synthetic tryptamines.
- The bigger risk is what the label leaves out. Tested gummies have contained undisclosed THC, mitragynine (kratom), ephedrine and caffeine.
- Psilocybin and psilocin can be detected by targeted lab methods such as LC-MS/MS, but these aren't part of routine panels.
- Employers and other programs can use their own panels, so nobody can promise a result.
What do standard drug tests look for?
The federal workplace urine panel, which HHS republished in March 2026, covers a marijuana metabolite, a cocaine metabolite, several opioids, phencyclidine (PCP), fentanyl, and amphetamines including MDMA. It doesn’t list psilocybin, psilocin, muscimol, mitragynine or synthetic tryptamines (Substance Abuse and Mental Health Services Administration (HHS), 2026).
That panel is mandatory only for federal agency programs. Private employers, courts, clinics and other regulated programs can choose different panels (Substance Abuse and Mental Health Services Administration (HHS), 2026). Ask whoever orders the test what it covers.
A 2017 laboratory-medicine review notes that routine screens can miss less common drugs. It says amphetamine screening tests react only weakly with psilocin, and that confirming psilocybin or psilocin needs GC-MS or LC-MS/MS (Dasgupta, 2017).
Why the label matters more than the mushroom
The question isn’t really whether mushrooms show up. It’s whether the gummy contains something that does. In published tests:
- A Portland gummy whose label listed only lion’s mane, reishi, cordyceps and a “proprietary microdosed nootropic blend” contained Δ9-THC and other cannabinoids (van Breemen et al., 2025).
- A separate Portland study found undisclosed THC in a product marketed as nootropic (Correia et al., 2025).
- A Virginia gummy labelled with Amanita, blue lotus and functional mushrooms contained mitragynine (kratom’s best-known alkaloid) as well as psilocin, DMT and caffeine. Another contained ephedrine (Michienzi et al., 2024).
THC is on the federal panel (Substance Abuse and Mental Health Services Administration (HHS), 2026). Whether any particular screen picks up a given amount of an undisclosed ingredient depends on the test and its cut-offs. We can’t predict that, and neither can the label.
How long is psilocin in your system?
In 12 healthy adults given pure oral psilocybin under supervision, no intact psilocybin was found in blood or urine. Psilocin, the active form, had an elimination half-life of about 3 hours (Brown et al., 2017). A half-life describes how fast blood levels fall. It isn’t a detection window, and it comes from a pure drug, not a retail gummy.
Questions people ask
Can a mushroom gummy make me fail a THC test?
It's possible if the gummy contains THC that isn't on the label. One Portland gummy listed only lion's mane, reishi, cordyceps and a 'nootropic blend' but contained Δ9-THC and other cannabinoids. Another 'nootropic' gummy contained undisclosed THC.
How long does psilocin stay in your body?
In a study of 12 healthy adults given pure psilocybin, psilocin had an elimination half-life of about 3 hours. That isn't the same as a detection window, which depends on the test and the lab's cut-off.
Sources
- Substance Abuse and Mental Health Services Administration (HHS). Mandatory Guidelines for Federal Workplace Drug Testing Programs: Authorized Testing Panels (FR Doc. 2026-04981). March 13, 2026.
The federal workplace urine panel covers a marijuana metabolite, a cocaine metabolite, codeine/morphine, hydrocodone/hydromorphone, oxycodone/oxymorphone, 6-acetylmorphine, phencyclidine, fentanyl, amphetamines and MDMA/MDA. It does not list psilocybin, psilocin, muscimol, mitragynine or synthetic tryptamines.
- Dasgupta A. Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse. Adv Clin Chem. 2017;78:163-186.
Routine urine drug-screening immunoassays target common drugs and may miss less common ones; amphetamine immunoassays have low cross-reactivity with psilocin; confirmation of psilocybin/psilocin needs GC-MS or LC-MS/MS methods.
- Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, et al.. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet. 2017;56(12):1543-1554.
In 12 healthy adults given oral psilocybin, no intact psilocybin was found in plasma or urine; the active metabolite psilocin had an elimination half-life of about 3 hours, and less than 2% was cleared unchanged by the kidneys.
- van Breemen RB, Simchuk D, Fritzsche B, Huson D, Kuzdzal SA, Ferguson J. Active Constituents of Psilocybin Mushroom Edibles. JAMA Netw Open. 2025;8(9):e2531345.
Tested 12 'magic mushroom' edibles (11 gummies, 1 chocolate) bought at retail shops in Portland, Oregon. None contained psilocybin. Eight contained active ingredients not disclosed on the label: psilocin (3), synthetic tryptamines mipracetin and 4-HO-DET (2), caffeine (1), kava extract (1) and cannabis extract including Δ9-THC (1). Four had no active ingredient detected. Muscimol and muscarine, listed on one label, were not detected in any product.
- Correia MS, Gonzaga MJ, Temple C, Gerona RR. Quantitative analysis of recreational psychoactive mushroom gummies in Portland, Oregon. Clin Toxicol (Phila). 2025;63(4):261-266.
Eight gummy products from seven Portland, Oregon smoke and vape shops, analysed by LC-QTOF-MS. Neither ibotenic acid nor muscimol was found in the two products claiming Amanita muscaria; seven of eight contained psilocin and six contained 4-AcO-DMT. One product labelled psilocybin-free tested positive for psilocybin; one 'nootropic' product contained undisclosed Δ9-THC; kavalactones were also detected.
- Michienzi A, Hamlin J, Farah R, Bazydlo L. Notes from the Field: Schedule I Substances Identified in Nootropic Gummies Containing Amanita muscaria or Other Mushrooms - Charlottesville, Virginia, 2023-2024. MMWR Morb Mortal Wkly Rep. 2024;73(28):628-630.
Blue Ridge Poison Center (Virginia) managed five people evaluated after eating gummies labelled as containing Amanita muscaria (Sept 2023–June 2024), including a 3-year-old who was hospitalised. Investigators bought six packages of five brands from gas stations and smoke shops; four of six contained unlabelled psilocybin or psilocin, with caffeine, ephedrine, mitragynine (kratom) and DMT among other unlabelled findings.